	US 11,981,738 B2
	ALK7 binding proteins and uses thereof
Ravindra Kumar, Acton, MA (US); Roselyne Castonguay, Watertown, MA (US); Dianne Sako, Medford, MA (US); Jonathan Belk, Lebanon, NH (US); and Nathan J. Sharkey, Lebanon, NH (US)
Assigned to Acceleron Pharma Inc., Cambridge, MA (US)
Appl. No. 16/757,959
Filed by Acceleron Pharma Inc., Cambridge, MA (US); and Adimab, LLC, Lebanon, NH (US)
PCT Filed Oct. 25, 2018, PCT No. PCT/US2018/057482 § 371(c)(1), (2) Date Apr. 21, 2020, PCT Pub. No. WO2019/084249, PCT Pub. Date May 2, 2019.
Claims priority of provisional application 62/577,038, filed on Oct. 25, 2017.
Prior Publication US 2020/0392233 A1, Dec. 17, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61P 3/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2863 (2013.01) [A61P 3/06 (2018.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/92 (2013.01)]

11 Claims

1. An Activin Receptor-Like Kinase 7 (ALK7)-binding protein that specifically binds a primary epitope of an ALK7 protein, wherein the primary epitope is an epitope selected from SEQ ID NOs:310, 313, and 317, wherein the ALK7-binding protein comprises a heavy chain variable region (VH) and light chain variable region (VL) pair, and wherein the VH and VL pair of the ALK7-binding protein has:

a) a VH sequence having at least 90% identity to SEQ ID NO: 117; and

b) a VL sequence having at least 90% identity to SEQ ID NO:124,

wherein the VH sequence comprises a set of CDRs:

(i) VH-CDR1 comprises an amino acid sequence of SEQ ID NO: 114;

(ii) VH-CDR2 comprises an amino acid sequence of SEQ ID NO: 115; and

(iii) VH-CDR3 comprises an amino acid sequence of SEQ ID NO: 116,

wherein the VL sequence comprises a set of CDRs:

(iv) VL-CDR1 comprises an amino acid sequence of SEQ ID NO:121;

(v) VL-CDR2 comprises an amino acid sequence of SEQ ID NO: 122; and

(vi) VL-CDR3 comprises an amino acid sequence of SEQ ID NO: 123,

and wherein the protein binds to ALK7.